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Rethinking
Schistosomiasis
Vaccine
Development:
Synthetic Vesicles
Moses Egesa,1,2
Karl F. Hoffmann,3
Cornelis H. Hokke,4
Maria Yazdanbakhsh,4 and
Stephen Cose2,5,*There is currently no vaccine
against schistosomiasis. With few
Schistosoma vaccine candidates
in clinical trials, unexplored anti-
gens from the vulnerable schisto-
somulum should be considered as
possible vaccine candidates. In
addition, we suggest developing
synthetic vesicles as a new deliv-
ery vehicle and adjuvant for immu-
noprophylactic schistosomula
vaccine candidates.It Is Time to Think Elimination
Schistosomiasis is one of the most preva-
lent parasitic diseases worldwide.
Treatment of schistosomiasis in at-risk
populations with a single dose of prazi-
quantel annually has not prevented trans-
mission of Schistosoma, and
[117_TD$DIFF]consequently reinfection is common in
endemic areas. The World Health Organi-
sation (WHO) reported that 219 million
people worldwide needed preventative
treatment against schistosomiasis in
2015. Of those who required treatment,
less thanone third received it throughmass
drug administration (MDA) programmes
[1]. Evenmoredisconcerting is thatmodel-
ling studies suggest that MDA will only
reduce the prevalence of schistosomiasis
if more than 70% of communities partici-
pate and the MDA is conducted annually
[2]. A drug-based strategy alone thereforemay not move national schistosomiasis
programs of low- to middle-income coun-
tries from morbidity control towards elimi-
nation [3]. Other interventions, working
alongsideMDA,suchasvaccination,could
effectively prevent reinfection, and thus
eliminate schistosomiasis. Vaccination
with radiation-attenuated cercariae pro-
tectsmurine and nonhuman primatemod-
els against challenges with schistosomes.
However, using radiation-attenuated cer-
cariae in human trials is impractical
because [118_TD$DIFF]they are difﬁcult to produce under
good manufacturing practice (GMP), and
deliveryof thevaccineunder liquid nitrogen
presents considerable logistical chal-
lenges. As a consequence, recombinant
antigens that can be easily produced are
being considered as potential subunit vac-
cine candidates (reviewed in [4]). Some of
these vaccine candidates are efﬁcacious
against challenge infection in animal mod-
els, but show low immunogenicity as puri-
ﬁed single antigens when tested further in
humanpreclinical tests.Therefore,wesug-
gest twoapproaches to improve the immu-
nogenicity of Schistosoma vaccine
antigens. Firstly, multiple, and not single,
antigens should beused [119_TD$DIFF] bothextracellular
vesicle [120_TD$DIFF](EV) and non-EV encoded] in the
developmentofa schistosomiasis vaccine.
Secondly, we consider synthetic vesicles
asaproof-of-concept antigen-deliveryand
adjuvant system. Schistosoma-shed
vesicles have been recently identiﬁed
[5,6], but whether we can design synthetic
stimulatory versions of these vesicles to
deliver Schistosoma vaccine targets is a
question yet to be addressed. This Forum
article examines the potential of using syn-
thetic vesicles as adjuvant and delivery
vehicle containing multiple schistosomula
vaccine candidates.
Targeting Schistosomula
Antigens [121_TD$DIFF]As Vaccine Candidates
The schistosomulum is the transition
phase between a free-living nonfeeding
cercaria in fresh water and the parasitic
blood ﬂuke in the mammalian host.
When cercariae penetrate human skin
they transform into the skin-stageschistosomula (Figure 1). The skin-stage
schistosomula upregulates speciﬁc
genes during transformation to facilitate
invasion and to survive the hostile host
immune response [7]. The schistosomula
also develops [122_TD$DIFF]both an inner and outer lipid
bilayer membrane covering the tegument
that facilitates survival within the host.
Just as the new coat develops, the early
postpenetration schistosomulum is vul-
nerable to host immune-mediated attack
[8]. The late-phase schistosomulum is
less susceptible to both eosinophil- and
macrophage-mediated cytotoxicity when
it develops towards adulthood. Early
schistosomulum antigens are therefore
possible candidates for the development
of a prophylactic vaccine against human
schistosome infections. However, there
are few current efforts to identify and pri-
oritise schistosomula antigens for a novel
vaccine. One such initiative was The-
SchistoVac consortium that targeted anti-
gens highly expressed by the skin
schistosomula for vaccine developmenti [116_TD$DIFF].
The work done provides a template for
future targeted (stage-speciﬁc) vaccine
development.
Schistosomes are complex multicellular
organisms, and this may partly explain
why current vaccines composed of a sin-
gle antigen are not capable of inducing
long-lived protective immunity. We
propose multiple-antigen preparations
to target different aspects of the early-
stage schistosomula ranging from tegu-
ment formation and turnover to metabo-
lite (glucose) uptake. In fact, the
multivalent chimeric schistosomiasis vac-
cine of SmTSP-2 and Sm29 induces
more robust immune responses com-
pared to single-antigen preparations in
mice [9]. Although identifying new anti-
gens based on the schistosomulum is a
critical step, combining new and existing
antigens as amultiple vaccine preparation
is, we believe, a necessary step in design-
ing the next generation of vaccines to a
complex, multicellular organism. We
would suggest both non-EV antigens
(to target the schistosomula) andTrends in Parasitology, Month Year, Vol. xx, No. yy 1
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Figure 1. Migration of Schistosomula through the Host Skin. 1. The cercaria is attracted to human skin. 2. The cercaria burrows through the skin and detaches
the bifurcated tail to form a schistosomulum. 3. The schistosomulum releases excretion/secretion (ES) products, including extracellular vesicles (EVs) that interact with
resident Langerhans cells, which migrate to skin draining lymph nodes to initiate adaptive immune responses. 4. The schistosomulum moves towards the basement
membrane that temporarily halts their migration. 5. Once in the dermis, the schistosomulum is vulnerable to antibody-mediated killing by granulocytes. 6. Schistosome-
induced cytokines activate more phagocytes and polarize the immune response towards inﬂammatory responses. 7. The schistosomulum penetrates dermal veins and
migrates to the lungs. 8. The schistosomulum is coated with host proteins as an immune evasion mechanism. The ﬁgure was adapted and modiﬁed from Servier
Medical Artii.EV-encoded antigens (to target secreted
EVs). Finally, the multiple-antigen vaccine
will require new tools, such as synthetic
vesicles, to be delivered to immune cells.
Synthetic Vesicles to Deliver
Schistosoma Vaccine Candidates
Schistosomes release excreted/secreted
(E/S) products to survive the hostile host
immune system. Among these products2 Trends in Parasitology, Month Year, Vol. xx, No. yycharacterised to date are Schistosoma-
shed extracellular vesicles (EVs) [5,6],
spherical structures encapsulated by a
lipid bilayer and shown to be responsible
for intercellular communication [10]. The
major subsets of EVs are exosomes,
microvesicles, and apoptotic bodies.
EVs are classiﬁed based on their biogen-
esis, their size, and what surface markers
they express. Of importance is thatSchistosoma EVs (derived from both
schistosomula and adult worms) contain
potential vaccine candidates, including
SmTSP-2 and Sm29 [5,6].
We suggest packaging schistosome vac-
cine antigens in synthetic vesicles
because naturally occurring Schistosoma
mansoni EVs may contain inhibitory bio-
logical material such as miRNAs and
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Table 1. Pros and Cons of Antigen Delivery via Synthetic Vesicles
Advantages EV[112_TD$DIFF]a [111_TD$DIFF] and non-EV antigens target both schistosomula and EVs, increasing immunogenicity
Antigen-presenting cells can be targeted by displaying speciﬁc ligands on the outer
surface of synthetic vesicles using GPIb [113_TD$DIFF] anchors
Adding molecules that activate antigen-presenting cells means that synthetic vesicles
are not just antigen-delivery vehicles, but also an adjuvant as well
Synthetic vesicles exhibit natural EV properties, such as stability and resistance to enzymatic degradation in body ﬂuids
Naturally occurring EV cargo, such as miRNA, with inhibitory properties, is avoided in synthetic vesicles
Synthetic vesicles lack host proteins, a potential mechanism for decreasing immunogenicity
Disadvantages Expensive to manufacture
Risk of reactogenicity associated with synthetic materials may lead to adverse effects in humans
Extensive regulatory requirements are expected for human use license
[114_TD$DIFF]aEV, extracellular vesicle.
bGPI, Glycosylphosphatidylinositol [115_TD$DIFF].tsRNAs [6]. Packaging parasite antigens
into vesicles will improve their antigenicity
compared to using the antigens directly
for vaccination [11]. Another advantage of
utilizing synthetic vesicles is that they are
free of host proteins that have been
described in EVs of other parasites such
as Echinostoma caproni and Fasciola
hepatica [12]. The proof-of-concept for
manufacturing synthetic vesicles already
exists with other lipid molecules such as
virus-like particles (VLPs) and outer-mem-
brane vesicles (OMVs). The pros and
cons of antigen delivery using synthetic
vesicles are summarised in Table 1. We
suggest that it is now time to take this
technology forward and target the
schistosome.
Vaccine candidates within vesicles are
also effectively protected from degrada-
tion as they move through body ﬂuids,
improving their stability within the host.
For synthetic vesicles to work as adju-
vants, additional ligands that target
receptors on antigen-presenting cells –
such as pathogen recognition receptors
on dendritic cells – could be added to the
vesicle surface using glycosylphosphati-
dylinositol (GPI) anchors for robust cellular
responses. With appropriate thought
given to the incorporation of mem-
brane-embedded glycoprotein ligands
or receptors, targeting speciﬁcimmunological cells could be engineered
and achieved. In addition to targeting the
actual schistosomula, immune responses
induced by synthetic vesicles (to EV-
encoded antigens) will also target and
neutralise Schistosoma EVs, decreasing
the ability of the schistosomula to
dampen immune responses and make
the environment less suitable for survival.
All in all, immune responses to multiple-
antigen preparations from the early phase
of the schistosomulum, packaged in syn-
thetic vesicles, may prevent development
of the adult schistosomes and subse-
quently the laying of eggs that cause
the pathology associated with
schistosomiasis.
Concluding Remarks
Although schistosomiasis is treatable,
reinfections are common in endemic
areas. It is widely acknowledged that a
vaccine used alongside chemotherapy
would control, and possibly eliminate,
schistosomiasis. We have suggested
using synthetic vesicles that are pre-
loaded with multiple schistosomula anti-
gens to elicit protective, skin-stage host
responses as a next-generation antischis-
tosomal vaccine. As we move towards
2025, the year that WHO has set to elimi-
nate schistosomiasis globally, these and
other novel approaches are required to
develop vaccines.[123_TD$DIFF] isclaimer Statement
The authors declare that there is no conﬂict of interest.
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